A 12-week preclinical study investigating continuous dietary fisetin supplementation in naturally aging female mice revealed no significant improvements in lifespan, physical function, or skeletal muscle contractility. The findings challenge the universal efficacy of fisetin as a systemic geroprotector and suggest its senolytic or anti-inflammatory benefits may require a pre-existing threshold of pronounced cellular stress to become clinically relevant.
The scientific community has increasingly positioned fisetin as a highly promising senolytic and anti-inflammatory compound. Previous literature demonstrates fisetin can clear senescent cells, reduce oxidative stress, and act on critical longevity pathways including mTOR, PI3K/Akt, and NF-kB. However, much of the foundational data supporting these benefits originates from models of acute injury, specific diseases, or genetically accelerated aging. This study sought to determine if those same therapeutic effects translate to normal, natural aging using a 12-week continuous dietary intervention in older female mice.
Researchers administered 500 parts per million fisetin formulated into standard rodent chow. The study tracked whole-body performance through distance to exhaustion, walking speed, voluntary activity, and grip strength, while also assessing ex vivo skeletal muscle contractility in the soleus and extensor digitorum longus. The results were definitively null across nearly all primary endpoints. Survival curves between the fisetin and control groups were identical. Furthermore, treating the animals with continuous fisetin failed to prevent age-related declines in muscle strength or cardiovascular endurance.
To explain these results, the authors propose a threshold of cellular stress model. In healthy natural aging, endogenous clearance mechanisms and biological buffers may adequately manage the slow accumulation of senescence and oxidative damage. Until tissue stress exceeds a specific pathological threshold, adding a systemic senolytic like fisetin provides no measurable functional advantage. The compound appears highly context-dependent, requiring a highly inflammatory or diseased environment to yield the dramatic physiological rescues seen in prior literature.
Actionable Insights
For individuals utilizing daily dietary supplements to optimize healthspan and delay sarcopenia, this data strongly suggests that continuous, prophylactic fisetin dosing provides no functional advantage in the absence of severe physiological stress or disease.
The practical effect size of fisetin on cardiovascular endurance and muscular strength in this healthy aging model was zero. The compound failed to alter the trajectory of physical decline. More concerning for longevity protocols, the intervention produced a negative biological outcome regarding body composition. Fisetin supplementation resulted in a statistically significant, unintended increase in body weight. Mice in the treatment group gained an average of 1.26 grams, while control mice lost 1.64 grams, resulting in a 2.90 gram absolute difference between cohorts. This weight gain correlated with an increased clinical frailty score in the treated animals.
These findings indicate that continuous daily fisetin consumption may not be an optimal strategy for healthy adults monitoring cardiovascular markers and body composition. The data supports transitioning away from chronic fisetin use in healthy individuals, as the compound lacks the efficacy to improve physical function without a background of acute metabolic or inflammatory dysfunction.
Context/Source
- Open Access Paper: Dietary fisetin does not improve physical function or muscle contractility in naturally aging female mice
- Institution: Boston University
- Country: USA
- Journal: Translational Exercise Biomedicine
- Impact Evaluation: The impact score of this journal is unranked, evaluated against a typical high-end range of 0 to 60 for top general science, therefore this is a Low impact journal.